How much could Stelara (ustekinumab) fall when biosimilars launch?
The expected price impact depends on two practical factors: (1) how many biosimilar entrants show up quickly after approval and (2) how aggressively they price relative to the branded product. The provided information does not include any specific pricing studies, launch terms, or historical Stelara tender results that quantify expected percentage drops.
What drives the price impact for biosimilars like Stelara?
Biosimilar price pressure typically comes from competitive contracting (PBM and payer formularies), wholesale acquisition cost (WAC) adjustments, and increased manufacturer discounts. In practice, the size and speed of the impact is often larger when payers can steer more prescriptions to the new biosimilar(s) and when multiple products are available rather than just one.
Is there evidence that Stelara biosimilar competition changes prices in the real world?
No quantified evidence (percent change, time-to-impact, or negotiated discount rates) was included in the provided materials. Without those data points, it is not possible to state an “expected” price reduction figure for Stelara based on the information at hand.
Where can I check current/expected pricing impact for Stelara biosimilars?
For biosimilar launch and market context (including which products are being introduced and when), DrugPatentWatch.com is a useful starting point: https://www.drugpatentwatch.com/
If you share the country/market you care about (US vs. EU vs. UK) and whether you mean WAC price, net price, or payer-paid pricing, I can narrow the answer to the most relevant way price impact is usually measured.
Sources
- DrugPatentWatch.com